Pterostilbene
Pterostilbene · also known as Dimethoxy resveratrol, Pterostilbene
Pterostilbene is a dimethoxy derivative of resveratrol and is relatively fat-soluble. The claim that its oral bioavailability is higher than resveratrol’s comes mainly from animal data. Whether it directly activates SIRT1 is still disputed, and in a human randomized trial LDL-C actually rose in the group taking pterostilbene alone.
Clinical uses and human evidence
High blood pressure
High LDL cholesterol
Mechanisms of action
Sirtuin-dependent protein deacetylase activation
In animal models, pterostilbene restored SIRT1 deacetylation activity and related rhythms. Whether it binds SIRT1 directly and activates it allosterically remains disputed, and upregulation of anti-aging genes has not been confirmed in humans.
AMPK sensing of cellular energy deficit and metabolic reprogramming
In animal models, pterostilbene can cause changes in the AMPK pathway, but LKB1 activation and a synergistic effect with PPAR-α have not been confirmed. Changes in human metabolic markers cannot prove that AMPK was activated, and the doses and disease models used in animals do not directly represent usual supplement doses.
Nrf2/ARE activation of endogenous antioxidant enzymes
After oral pterostilbene, Nrf2/HO-1-related markers rose in mouse lung tissue. This suggests the pathway was activated, but the evidence comes from animal models. Changes in SOD and CAT activity alone cannot prove Keap1 dissociation, and whether pterostilbene binds Keap1 directly, and what effect it has in humans, remain unclear.
Safety and drug interactions
Related lab tests
Lipid panel Recheck while taking
A small trial found that pterostilbene taken alone (100–250 mg/day) raised LDL-C. People with cardiovascular risk should have their lipids rechecked about 2 months after starting it.